TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31841156

Group type: EXPERIMENTAL
Intervention: SupportBack Internet intervention with physiotherapist telephone guidance
Number of subjects: 15

Group type: COMPARATOR
Intervention: SupportBack Internet intervention without physiotherapist telephone guidance
Number of subjects: 15
Study: 29746388

Group type: EXPERIMENTAL
Intervention: β-Alanine (BA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 28126631

Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI) group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All-capital-letters task
Number of subjects: 37
Study: 26207129

Group type: EXPERIMENTAL
Intervention: Clzapine (generic formulation) 100 mg twice daily for 10 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Clozaril (brand name formulation) 100 mg twice daily for 10 days
Number of subjects: 28
Study: 24114865

Group type: EXPERIMENTAL
Intervention: High-dose β-blocker (≥50 mg daily equivalent dose of metoprolol succinate)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Low-dose β-blocker (<50 mg daily equivalent dose of metoprolol succinate)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Low-dose β-blocker with high sST2
Number of subjects: 151

Group type: COMPARATOR
Intervention: Low-dose β-blocker with low sST2
Number of subjects: 151

Group type: COMPARATOR
Intervention: High-dose β-blocker with high sST2
Number of subjects: 151
Study: 20820172

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (45 minutes of moderate-to-vigorous aerobic exercise five times per week for 1 year)
Number of subjects: 320
Study: 18650733

Group type: EXPERIMENTAL
Intervention: Systemic alendronate for 4 months starting the day of surgery (group 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Systemic alendronate + postextractive endoalveolar collagen sponge (group 4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Postextractive endoalveolar collagen sponge (group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No medication (group 1)
Number of subjects: 40
Study: 17049927

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral intervention (CBI)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Treatment with counseling as usual (TAU)
Number of subjects: 104
Study: 12624515

Group type: EXPERIMENTAL
Intervention: Flow cytometry with propidium iodide staining and anti-cytokeratin antibodies
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Double labelling technique with cytokeratin-staining
Number of subjects: 30

Group type: COMPARATOR
Intervention: Forceps biopsies
Number of subjects: 30
Study: 10693733

Group type: EXPERIMENTAL
Intervention: SunSafe intervention
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control town parents
Number of subjects: 261
Study: 7568736

Group type: EXPERIMENTAL
Intervention: Counterrotational electric toothbrush
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 20
Study: 2405623

Group type: EXPERIMENTAL
Intervention: High-dose calcium heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose calcium heparin
Number of subjects: 0
Study: 7380584

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30787664

Group type: EXPERIMENTAL
Intervention: Foam rolling (short duration 20s)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Foam rolling (long duration 40s)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Joint distraction with elastic band training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 53
Study: 27106713

Group type: EXPERIMENTAL
Intervention: Mindset intervention
Number of subjects: 726

Group type: COMPARATOR
Intervention: Content writing task
Number of subjects: 726
Study: 25651595

Group type: EXPERIMENTAL
Intervention: Creative dance program for 24 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study: 22840783

Group type: EXPERIMENTAL
Intervention: GAD1 gene risk variants (tSNP rs3828275)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: GAD1 gene risk variants (tSNP rs769391 and functional SNP rs3791878)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Subjects with 0-1 risk variant
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Haplotypes with both risk variants
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Diplotype with 2 copies of the haplotype containing both risk alleles
Number of subjects: 257
Study: 20825817

Group type: EXPERIMENTAL
Intervention: Point-of-care chemistry test (POCT)
Number of subjects: 2323

Group type: COMPARATOR
Intervention: Traditional central laboratory test (CLT)
Number of subjects: 2323
Study: 19034910

Group type: EXPERIMENTAL
Intervention: Dual-pathway model of overeating
Number of subjects: 153
Study: 17908768

Group type: EXPERIMENTAL
Intervention: Overweight group (BMI for age: > or = 95th percentile)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Overweight risk group (BMI for age: 85th to < 95th percentile)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Overweight group
Number of subjects: 1005

Group type: COMPARATOR
Intervention: General population of children in the United States
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Black and Hispanic children
Number of subjects: 1005
Study: 15331679

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) ‐20 mmHg in +RA subjects
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) ‐20 mmHg in ‐RA subjects
Number of subjects: 23

Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP) ‐40 mmHg in controls
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) ‐40 mmHg in +RA subjects
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) ‐40 mmHg in ‐RA subjects
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) response to LBNP ‐40 mmHg in ‐RA subjects
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) response to LBNP ‐40 mmHg in +RA subjects
Number of subjects: 23

Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) response to LBNP ‐40 mmHg in controls
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Heart rate response from baseline to LBNP ‐40 mmHg in ‐RA subjects
Number of subjects: 23
Study: 11247108

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 to 20 mg/day)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Haloperidol (5 to 20 mg/day)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Olanzapine vs Haloperidol
Number of subjects: 676
Study: 9754892

Group type: EXPERIMENTAL
Intervention: ATHU-test (AHEPA Thromb Haem Unit)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ATHU-test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: In vitro addition of LMWH (1.5 u aXa/ml)
Number of subjects: 20
Study: 7722707

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (100 kcal/d) during the first year of life
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (100 kcal/d) during the second year of life
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation between 24 and 36 months of age
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation between 3 and 7 years of age
Number of subjects: 1208
Study: 2816762

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 1111271

Group type: EXPERIMENTAL
Intervention: Informational load of 1, 2, and 3 bits; manual motion distances of 7 inches and 14 inches.
Number of subjects: 5
Study: 30113394

Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 97

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 97
Study: 28825663

Group type: EXPERIMENTAL
Intervention: Letibotulinumtoxin A
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A
Number of subjects: 144
Study: 26157206

Group type: EXPERIMENTAL
Intervention: Neurac training (30 min/day, 3 days/week for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional physical therapy (30 min/session, 3 sessions/week for 4 weeks)
Number of subjects: 20
Study: 23475153

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study: 21707176

Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19381808

Group type: EXPERIMENTAL
Intervention: Neighborhood strength
Number of subjects: 5655

Group type: EXPERIMENTAL
Intervention: Exposure to alcohol advertisements
Number of subjects: 5655

Group type: EXPERIMENTAL
Intervention: Commercial alcohol access
Number of subjects: 5655

Group type: EXPERIMENTAL
Intervention: Home alcohol access
Number of subjects: 5655
Study: 16943451

Group type: EXPERIMENTAL
Intervention: Fish oil plus 100 mg vitamin E
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fish oil plus 200 mg vitamin E
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fish oil plus 400 mg vitamin E
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fish oil only (control)
Number of subjects: 40
Study: 15364138

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT) alone (20Gy in five fractions)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy plus concomitant carboplatin (70 mg/m(2) intravenously for 5 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (RT) arm
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy plus concomitant carboplatin (RTC) arm
Number of subjects: 42
Study: 10660240

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine (0.125 mg/kg/h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (0.25 mg/kg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (6 to 11 mL/h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (0.1% ropivacaine, 0.2% ropivacaine, saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 9549636

Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riluzole 100 mg for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Riluzole with high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riluzole 75 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Riluzole 50 mg three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-dose administration of riluzole
Number of subjects: 0
Study: 8157048

Group type: EXPERIMENTAL
Intervention: 2 mg i.v. dose of flumazenil
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30 mg oral dose of flumazenil
Number of subjects: 18
Study: 3895918

Group type: EXPERIMENTAL
Intervention: Ceftazidime (50 mg/kg intravenously every eight hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin plus chloramphenicol (conventional dosages)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin plus chloramphenicol
Number of subjects: 100
Study: 30196968

Group type: EXPERIMENTAL
Intervention: HFF/CGC‐IVM
Number of subjects: 47

Group type: COMPARATOR
Intervention: S‐IVM
Number of subjects: 47

Group type: COMPARATOR
Intervention: AFF‐IVM
Number of subjects: 47

Group type: COMPARATOR
Intervention: HFF‐IVM
Number of subjects: 47
Study: 26990651

Group type: EXPERIMENTAL
Intervention: Amplitude training (experimental group, n = 18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Stretch and relaxation exercises (placebo group, n = 20)
Number of subjects: 38
Study: 24472587

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich fluid group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 44
Study: 22891356

Group type: EXPERIMENTAL
Intervention: DCE MR imaging
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: DCE CT
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: DCE MR imaging and DCE CT
Number of subjects: 29
Study: 19305278

Group type: EXPERIMENTAL
Intervention: Mears technique
Number of subjects: 21
Study: 17207678

Group type: EXPERIMENTAL
Intervention: Circuit Resistance Training (CRT)
Number of subjects: 7
Study: 15254055

Group type: COMPARATOR
Intervention: Regimen A (vincristine 2 mg/m(2), cyclophosphamide 1,200 mg/m(2), doxorubicin 75 mg/m(2) or dactinomycin 1.25 mg/m(2))
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Regimen B (Regimen A alternating every 3 weeks with ifosfamide 1,800 mg/m(2)/d for 5 days and etoposide 100 mg/m(2)/d for 5 days)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Patients with only lung metastases
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Toxic deaths
Number of subjects: 120
Study: 11480629

Group type: EXPERIMENTAL
Intervention: A/V eyeglass system
Number of subjects: 27

Group type: COMPARATOR
Intervention: Traditional treatment (no A/V eyeglasses)
Number of subjects: 27
Study: 9493260

Group type: EXPERIMENTAL
Intervention: New randomization-based procedure with Bayesian analysis under the exclusion hypothesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intent-to-treat procedure
Number of subjects: 0
Study: 7946694

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel decompression
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional surgical treatment of open carpal tunnel decompression
Number of subjects: 18
Study: 3060211

Group type: EXPERIMENTAL
Intervention: Methylphenidate (low-dose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methylphenidate (long-term)
Number of subjects: 15
Study: 7438771

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 87

Group type: COMPARATOR
Intervention: Dextropropoxyphene plus paracetamol
Number of subjects: 87
Study: 31733490

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 174
Study: 31101694

Group type: EXPERIMENTAL
Intervention: 0.5% isobaric bupivacaine (1.15-1.70 mL) injected into the subarachnoid space without prophylactic vasopressors
Number of subjects: 264

Group type: COMPARATOR
Intervention: 0.5% bupivacaine (1.8 mL) injected into the subarachnoid space along with prophylactic vasopressors
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: 0.5% isobaric bupivacaine (1.15-1.70 mL)
Number of subjects: 264

Group type: COMPARATOR
Intervention: 0.5% bupivacaine (1.8 mL) with prophylactic vasopressors
Number of subjects: 264
Study: 27491027

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) therapy with the InterStim® System
Number of subjects: 272
Study: 25915772

Group type: EXPERIMENTAL
Intervention: Central PRO coordinator
Number of subjects: 231

Group type: COMPARATOR
Intervention: No PRO coordinator
Number of subjects: 231
Study: 23921584

Group type: EXPERIMENTAL
Intervention: RHANI Wives HIV intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Basic HIV prevention education (Control)
Number of subjects: 220
Study: 21248183

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 18978177

Group type: EXPERIMENTAL
Intervention: Resistant starch (RS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ordinary starch (OS)
Number of subjects: 65
Study: 17304501

Group type: EXPERIMENTAL
Intervention: Tritherapy strategy 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tritherapy strategy 2
Number of subjects: 0
Study: 15491578

Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Yuzpe regimen
Number of subjects: 1000
Study: 11427836

Group type: EXPERIMENTAL
Intervention: Maintenance endoscopic variceal ligation (EVL)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Demand endoscopic variceal ligation (EVL)
Number of subjects: 109
Study: 9745414

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (including high dose i.v. methotrexate)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High dose i.v. methotrexate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (children who did not receive high dose i.v. methotrexate)
Number of subjects: 22
Study: 7997610

Group type: EXPERIMENTAL
Intervention: Iopentol 350 mgI/ml
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iopamidol 370 mgI/ml
Number of subjects: 100
Study: 3377206

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg lorazepam intravenously
Number of subjects: 15

Group type: COMPARATOR
Intervention: 1.5 mg/kg secobarbital
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 15
Study: 4853118

Group type: EXPERIMENTAL
Intervention: Use of a checklist for side effect collection
Number of subjects: 0

Group type: COMPARATOR
Intervention: No checklist for side effect collection
Number of subjects: 0
Study: 30864279

Group type: EXPERIMENTAL
Intervention: Soybean oil-based parenteral lipid emulsion (PLE), n = 35
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: n-3-enriched parenteral lipid emulsion (PLE), n = 31
Number of subjects: 66

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 66
Study: 29666120

Group type: EXPERIMENTAL
Intervention: IOL Vivinex XY1
Number of subjects: 66
Study: 29145410

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive flexibility training
Number of subjects: 97

Group type: COMPARATOR
Intervention: Mock training (active control)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 97
Study: 25569185

Group type: EXPERIMENTAL
Intervention: SMART regimen (budesonide/formoterol)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard regimen (salbutamol)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 303
Study: 23620938

Group type: EXPERIMENTAL
Intervention: Fire needle combined with narrow band ultraviolet-B (NB-UVB) therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Narrow band ultraviolet-B (NB-UVB) therapy
Number of subjects: 93
Study: 21148423

Group type: EXPERIMENTAL
Intervention: Recombinant human TSP-1
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: TSP-1(−/−) mice
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Injections of TSP-1 in C57Bl6/J mice after hindlimb ischemia
Number of subjects: 184
Study: 18991190

Group type: EXPERIMENTAL
Intervention: Anti-TNFalpha treatment (adalimumab and infliximab) for 18 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Anti-TNFalpha treatment
Number of subjects: 12
Study: 17663340

Group type: EXPERIMENTAL
Intervention: Occlusal adjustment and filling (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Porcelain complete veneer crown (Group B)
Number of subjects: 60
Study: 15178468

Group type: EXPERIMENTAL
Intervention: Low-stress condition (n=21)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-stress condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Masked presentations of snake words
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Masked Stroop interference
Number of subjects: 40

Group type: COMPARATOR
Intervention: Age- and sex-matched controls (n=21)
Number of subjects: 40
Study: 11572248

Group type: EXPERIMENTAL
Intervention: Neck dissection followed by chemoradiotherapy (Group I)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Chemoradiotherapy alone (Group II)
Number of subjects: 54
Study: 9692392

Group type: EXPERIMENTAL
Intervention: Piperacillin plus ciprofloxacin (PC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Piperacillin plus gentamicin (PG)
Number of subjects: 96
Study: 7939369

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (3.4 g eicosapentaenoic and docosahexaenoic acid per day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids and Control group combined
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids and Control group
Number of subjects: 57
Study: 3330601

Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Cimetidine 800 mg
Number of subjects: 69
Study: 31813076

Group type: EXPERIMENTAL
Intervention: Experiencing internalized stigma
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Experiencing anticipated stigma
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Experiencing intimate partner violence (IPV)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Experiencing IPV
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Experiencing depression
Number of subjects: 200
Study: 29611500

Group type: EXPERIMENTAL
Intervention: Ceramic water filters (CWFs)
Number of subjects: 240
Study: 28882920

Group type: EXPERIMENTAL
Intervention: HAT TRICK programme (12-week face-to-face intervention)
Number of subjects: 60
Study: 26187227

Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMAs)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Individual annual appointments
Number of subjects: 272
Study: 24139135

Group type: EXPERIMENTAL
Intervention: Catheter venography (CV) + Intravascular ultrasound (IVUS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Magnetic resonance venography (MRV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Doppler sonography (DS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noninvasive screening methods
Number of subjects: 20
Study: 21178598

Group type: EXPERIMENTAL
Intervention: Combined therapy group (240 mg lidocaine in 125 mL saline once a week for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monotherapy group (25 mg amitriptyline with 125 mL saline)
Number of subjects: 30
Study: 18315472

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Terazosin (2 mg daily)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 95